ArticleFrontiers in oncology2025
Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating lncRNA data for prediction of miRNA-disease association using network fusion and matrix completion.Journal of computer-aided molecular design · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Introduction: Pancreatic cancer, mostly presenting as pancreatic ductal adenocarcinoma (PDAC), has a poor prognosis. The microsatellite-instable (MSI-H)/mismatch repair deficient (MMRd) subtype, however, is more susceptible to immune therapy and is expected to have a better prognosis. Presently, MSI-testing is not routinely performed on PDAC. We assessed whether quantitative imaging features (radiomics) of pretreatment computed tomography (CT) scans could diagnose MSI-H/MMRd. Methods: For this pilot study, we analyzed CT-scans of treatment-naïve sporadic or Lynch syndrome (LS)-associated MSI-H or MMRd PDACs, diagnosed or treated in a single center from 2007 to August 2022. CT-scans of resected MSI-stable, MMR proficient, non-LS PDACs formed a control group, after random selection in 1:4 ratio. Upon CT-scan segmentation, 254 well-defined radiomic features were extracted from pancreas and tumor regions. The predictability of the features was assessed within a repeated stratified 3-fold cross-validation framework by designing three models using random forest classifier, with the most discriminating features selected through the minimum redundancy maximum relevance method from three feature sets: tumor radiomics, pancreas radiomics, and combined tumor + pancreas radiomics. Performance was evaluated by area under receiver operating curve (AUC), sensitivity, specificity, positive and negative predictive value. Results: Overall, 95 patients were included: 19 patients with MSI-H/MMRd/LS (36.8% female; median age at diagnosis 72 [IQR 60-77 years]) and 76 matched controls with PDAC (53.9% female; median age at diagnosis 66 [IQR 57-74 years]). Median year when CT-scan was done was 2017 and 2018, respectively. The model using radiomic features from the pancreatic tumor reflecting MSI-H/MMRd, had an area under receiver operating curve (AUC) of 0.73. The performance of the model was improved by also incorporating radiomic features from pancreas texture (AUC of combined model 0.83 sensitivity 84%, specificity 78%, negative predictive value 95%). Conclusions: This pilot study suggests that radiomic features could be used to determine MSI/MMRd status in CT-scans of PDAC, but needs further independent multi-site validation in larger cohorts. Routine application of radiomics to determine MSI-status might be of interest in clinical practice to select patients who could benefit from immune therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.